Welcome to the e-CCO Library!

DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

Created: Friday, 22 February 2019, 9:41 AM
DOP51: De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation
Year: 2021
Source: ECCO'21 Virtual
Authors: Thomas, P.(1);Smits, L.(1);Te Groen, M.(1);West, R.(2);Russel, M.(3);Jansen, J.(4);Römkens, T.(5);Hoentjen, F.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP51: Loss of PTPN23 in the intestinal epithelium results in epithelial hyperproliferation and lethal diarrhea in a microbiota dependent manner
Year: 2022
Source: ECCO'22
Authors: Spalinger, M.(1);Sanchez Alvarez, R.(1);Gottier, C.(1);Montalban-Arques, A.(1);Schwarzfischer, M.(1);Niechcial, A.(1);Scharl, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: HagemanMD, I.(1)*;Joustra, V.(2);Zafeiropoulou , K.(1);Davids, M.(3);Hakvoort, T.(1);Probert, F.(4);Satsangi, J.(5);D'Haens, G.(2);De Jonge, W.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP52 The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s disease or ulcerative colitis reflects the respective disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Unterweger1, J. Caesar1, P. Winkelmann1, A. Rüscher1, M. Seuß1, S. Breiteneicher5, J. Stallhofer5, F. Beigel5, M. Siebeck1, R. Gropp1

Created: Thursday, 30 January 2020, 10:12 AM
DOP52: Development of a host-microbe interaction workflow to reveal the cell- and condition-specific effects of a commensal bacteria upon IBD
Year: 2022
Source: ECCO'22
Authors: Potari-gul, L.(1);Modos, D.(1,2);Fonseca, S.(2);Madgwick, M.(1,2);Thomas, J.P.(1,3);Sudhakar, P.(1,2,4);Booth, C.(5);Stentz, R.(2);Carding, S.R.(2,6);Korcsmaros, T.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
DOP52: Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn*1, B. Sands2, T. Kobayashi3, J. Tuttle4, J. Schmitz5, M. Durante5, R. Higgs5, J. B. Canavan5, R. Siegel5, M. Ferrante6

Created: Friday, 22 February 2019, 9:41 AM
DOP52: Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)
Year: 2021
Source: ECCO'21 Virtual
Authors: Chaparro, M.(1);García Donday, M.(1);Calviño Suarez, C.(2);Rubio, S.(3);Figueira, M.(4);Pérez Martínez, I.(5);Leo Carnerero, E.(6);Rodríguez Lago, I.(7);Ruiz Cerulla, A.(8);Aguas, M.(9);López Serrano, P.(10);Ramírez de la Piscina Urraca, P.(11);Rivero, M.(12);Suarez Ferrer, C.(13);Alfambra Cabrejas, E.(14);Armesto, R.(15);Diz-Lois Palomares, M.T.(16);Guerra, I.(17); Vázquez Morón, J.M.(18); Casanova, M.J.(1);Hervías Cruz, D.(19); Huguet, J.M.(20); de Jorge Turrión, M.Á.(21); Marín Pedrosa, S.(22);Molina Arriero, G.(23);Ramos, L.(24);Zúñiga de Mora-Figueroa, B.(25);Camargo Camero, R.(26);Fernández-Clotet, A.(27);Gutiérrez Casbas, A.(28);Martínez Montiel, P.(29);Rodríguez Insa, R.(30);Sendra Rumbeu, P.(31);Tardillo Marín, C.(32);Vicente Lidón, R.(33);Arias García, L.(34);Bujanda, L.(35);Lucendo, A.J.(36);Manceñido Marcos, N.(37);Gisbert, J.P.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP52: The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn's disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gerasimidis, K.(1)*;Nichols, B.(1);Papadopoulou, R.(1);Ijaz, U.(2);Rajendran, R.(3);Quince, C.(4);Russell, R.K.(5);Hansen, R.(6);Ramage, G.(3);
Created: Friday, 14 July 2023, 10:43 AM
DOP53 PTPN2 and TiO2 in the pathogenesis of inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Conde, M. Schwarzfischer, E. Katkeviciute, J. Häfliger, A. Niechcial, N. Brillant, K. Atrott, K. Bäbler, M. Scharl

Created: Thursday, 30 January 2020, 10:12 AM
DOP53: Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Sandborn1, D. Nguyen2, B. Ferslew2, L-Y. Hao3, T. Kanno3, L. Tomsho3, D. Boyle1, R. Graham2, B. Abhyankar2, J. Panes*4

Created: Friday, 22 February 2019, 9:41 AM
DOP53: Community types of the human gut virome are associated with endoscopic outcome in UC patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jansen, D.(1)*;Falony, G.(2);Vieira-Silva, S.(3);Simsek, C.(1);Marcelis, T.(1);Machiels, K.(4);Caenepeel, C.(4);Raes, J.(2);Severine, V.(4);Matthijnssens, J.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP53: In-depth characterisation of the serum antibody epitope repertoire in Inflammatory Bowel Disease by high-throughput phage-displayed immunoprecipitation sequencing
Year: 2022
Source: ECCO'22
Authors: Bourgonje, A.R.(1);Andreu-Sánchez, S.(2,3);Vogl, T.(4,5);Hu, S.(1,2);Vich Vila, A.(1,2);Leviatan, S.(4,5);Kurilshikov, A.(2);Klompus, S.(4,5);Kalka, I.N.(4,5);van Dullemen, H.M.(1);Weinberger, A.(4,5);Visschedijk, M.C.(1);Festen, E.A.M.(1);Faber, K.N.(1);Wijmenga, C.(2);Dijkstra, G.(1);Segal, E.(4,5);Fu, J.(2,3);Zhernakova, A.(2);Weersma, R.K.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP53: Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Dubinsky, M.C.(1);Mahadevan, U.(2);Charles, L.(3);Afsari, S.(3);Henry, A.(3);Comi, G.(4);Selmaj, K.(5);van der Woude, C.J.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP54 Integrated network analysis using patient-specific single-nucleotide polymorphism profiles uncovers new pathways involved in ulcerative colitis pathogenesis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Modos1,2,3, J. Brooks2,3,4, P. Sudhakar2,3,5, B. Verstockt5,6, B. Alexander-Dann1, A. Zoufir1, D. Fazekas2,7, S. Vermeire5,6, T. Korcsmaros2,3, A. Bender1

Created: Thursday, 30 January 2020, 10:12 AM
DOP54: Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Danese*1, B. E. Sands2, C. D. O'Brien3, H. Zhang3, J. Johanns3, S. Sloan3, J. Izanec4, P. Szapary3, C. Marano3, R. W. Leong5,6, D. Rowbotham7,8, S. R. Targan9, G. Van Assche10

Created: Friday, 22 February 2019, 9:41 AM
DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract
Year: 2022
Source: ECCO'22
Authors: Shilova, I.(1);La Chat, C.(1);Nigatu, E.(1);Messner, E.(1);Desnoyer, J.(1);Willcoxon, M.(1);Banas, S.(1);Ravichandar, D.(2);Narayan, N.(2);DeSantis, T.(2);Dabbagh, K.(1);Yamamoto, L.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP54: Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Jeuring, S.F.G.(1);Mujagic, Z.(1,2);Romberg-Camps, M.J.L.(3);van Bodegraven, A.A.(3);Jonkers, D.M.A.E.(1,2);Pierik, M.J.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP54: Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn's disease – a systematic review and network meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Attauabi, M.(1,2)*;Steenholdt, C.(1);Burisch, J.(2,3);Gubatan, J.(4);Nielsen, O.H.(1);Seidelin, J.B.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Mantzaris1, B. Bressler2, U. Kopylov3, M. Bassel4, N. Brett4, C. Colby5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, A. Yarur12

Created: Thursday, 30 January 2020, 10:12 AM